|
|
|
|
Document Preview Development Agreement |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Development Agreement |
|||
|
Entities: |
||||
|
Date: |
2001 |
|||
|
Size: |
Preview shows 1KB of 5KB total |
|||
|
Price: |
$39 |
|||
|
ID: |
#326459 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
This Agreement is made and entered into on this 20th day of July, 1999 ("Effective Date") between Seattle Genetics, Inc. ("Seattle Genetics"), a Delaware corporation with offices at 22215 26th Avenue, Bothell, WA 98021 and GTC Corporation ("GTC"), a Massachusetts corporation with offices at 175 Crossing Boulevard, Framingham, MA 01701-9322.
Whereas, Seattle Genetics and GTC agree to collaborate under the following terms and conditions on the further development of humanized huBR96-2 mAb with the intent of determining the clinical and commercial potential for this version of BR96. In consideration of the mutual promises and covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
|
End of Preview |
Home Intelligence Services Subscriptions News About Us